ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER
(Thomson Reuters ONE) -
GHENT, Belgium, 13 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief
Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the
Company's business development and corporate strategy activities and become a
member of the Executive Committee. Dr Ewert has worked for nearly 30 years in
the life sciences industry and has held a number of senior business and
commercial positions.
Until recently, Dr Ewert headed the Business Development team of the Healthcare
division of General Electric and in that capacity executed numerous deals. Prior
to that, he worked at Novartis in its Cardiovascular and Metabolism franchise
and later moved to the Molecular Diagnostics unit as Head of Strategy, Global
BD&L, and M&A. Before joining Novartis, Dr Ewert was CEO of two biotech
companies and had been at The Boston Consulting Group serving as an advisor to
pharmaceutical and chemical companies.
Dr Ewert holds a PhD in molecular biology from the University of Heidelberg and
an MBA from the University of Chicago.
Welcoming Dr Ewert to the team, Dr Edwin Moses, CEO of Ablynx, said:
"Markus brings extensive experience in leading business development teams and
executing licensing deals and acquisitions. Having held senior positions in big
pharma as well as in biotech and consultancy firms, he is ideally suited to
become part of our Executive Committee and play an important role in helping
Ablynx achieve its business objectives."
Commenting on his appointment, Dr Ewert added:
"I am very excited to join the Ablynx team and lead their business development
and strategy activities. Ablynx's Nanobody® platform has been clearly
demonstrated to be a very powerful tool in the development of potentially new
and important therapeutics. I am looking forward to strengthening the company's
existing relationships with pharmaceutical companies, creating new partnering
and strategic opportunities to further build the product pipeline, and advancing
the company."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co.,
Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company
is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx(at)fticonsulting.com
pdf version of the press release:
http://hugin.info/137912/R/2112625/803511.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.06.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 547503
Anzahl Zeichen: 4450
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
